tbuckley/cabot-search huggingface dataset:
Abstract 18318: Percutaneous Epicardial Access for Mapping and Ablation is Feasible in Patients With Prior Cardiac Surgery, Including Coronary Bypass Surgery
Authors: Ammar M Killu, Elisa Ebrille, Samuel J Asirvatham, Thomas M Munger, Christopher J McLeod, Douglas L Packer, Paul A Friedman, Siva K Mulpuru
Journal: Circulation (2014)

Introduction: Prior cardiac surgery, especially the presence of coronary bypass grafts, is thought to preclude percutaneous epicardial access (EpiAcc) and, due to limited catheter maneuverability, mapping and ablation. The objective of our study was to evaluate the feasibility and safety of EpiAcc in patients with prior cardiac surgery. Methods: We retrospectively analyzed all patients who underwent EpiAcc as part of an ablation procedure between 01/01/2004-06/30/2013 at Mayo Clinic, Rochester, MN. All had documented VT or recurring, symptomatic PVCs. Baseline clinical characteristics and procedural characteristics were collected. Results: Of 162 patients that underwent EpiAcc, 18 had prior cardiac surgery (mean age 61 years, all male). This included 10 CABG, 2 epicardial ICD placement, 5 valve surgery (3 aortic valve, 2 mitral valve), 2 septal myectomy, 1 aortic arch replacement, 1 myocardial bridge unroofing and 1 myocardial perforation repair (3 patients had multiple procedures). Access was successful in 12 patients (66.7%); the inferior approach was utilized in 78%. Of patients with prior CABG, successful access was attained in 6 (60%). The average procedural time was 441.6 ± 141.3 minutes. Adhesiolysis was required in 10 patients with the sheath, access wire, pigtail catheter or ablation catheter. Intra-procedural coronary angiography was performed in 8 patients. There were a total of 45 VTs/PVCs ablated in 18 patients (average 2.5 ± 1.7), mean cycle length 463.6 ± 95.9ms. Ultimately, 12 patients (66.7%) underwent endocardial only ablation, 1 (5.5%) had epicardial only ablation while 5 (27.8%) had endocardial/epicardial ablation. The procedure was deemed successful in 13 patients (72.2%). Four patients had bleeding complications (pericardial effusion, pericardial hematoma, hemoperitoneum and pericardial tamponade [the latter required repair of the RV wall]). In patients with coronary grafts, there was no evidence of acute graft disruption. Conclusions: Percutaneous epicardial access is feasible in patients with previous cardiac surgery, including CABG. However, adhesiolysis is frequently required. Although the risk of coronary graft injury is low, life-threatening complications may occur.
Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study.
Authors: H C Falkson, R Gray, W H Wolberg, K W Gillchrist, J E Harris, D C Tormey, G Falkson
Journal: Journal of Clinical Oncology (1990)

A prospectively controlled randomized trial to compare the adjuvant efficacy of 12 cycles of cyclophosphamide, methotrexate, fluorouracil, prednisone, and tamoxifen (CMFPT) followed by observation or a total of 5 years of continuous tamoxifen versus four cycles of CMFPT followed by observation in postmenopausal women with operable node-positive breast cancer was started by the Eastern Cooperative Oncology Group (ECOG) in 1982. In 1986 the study was modified to allow patients on CMFPT X 12 plus continuous tamoxifen to be rerandomized after completing 5 years of tamoxifen to either continue for life or to stop therapy. Patients were stratified for number of involved nodes and estrogen-receptor (ER) status and randomized to receive one of three treatments: CMFPT X 4, CMFPT X 12, or CMFPT X 12 plus continuous tamoxifen. Of 962 patients entered on the study, 803 were eligible. Life-threatening toxicity occurred in 75 and lethal toxicity in seven patients. Median follow-up is 4.1 years; 279 patients had recurrent disease. Time to relapse (TTR) is significantly longer for patients on CMFPT X 12 plus continuous tamoxifen than for CMFPT X 4 (P = .002), or CMFPT X 12 (P = 0.05). Differences between four or 12 cycles of CMFPT are not significant; relapse-free rates at 5 years are 61% for CMFPT X 12 plus continuous tamoxifen, 51% on CMFPT X 12, and 52% on CMFPT X 4. Treatment differences in overall survival are not significant. Hormone receptor status and number of involved nodes were found to be significant prognostic parameters.
Quality of Life (Qol) on the Aflibercept/Folfiri Regimen: 4Th Interim Analysis of the Global Aflibercept Safety and Health-Related Qol Program
Authors: J. Taieb, R. Bordonaro, K. Bencardino, L. Ciuffreda, F. Di Costanzo, M. Di Bartolomeo, A.L. Thomas, H. Kröning, P. García Alfonso, C. Borg, Y. Moore, S. Brette, C. Zilocchi, F. Joulain, S. Naoshy, P. Garreau-Laporte, E. Dochy, G. Lledo, A. Sobrero
Journal: Annals of Oncology (2014)
Pre-pregnancy potato consumption and risk of gestational diabetes mellitus: prospective cohort study
Authors: Wei Bao, Deirdre K Tobias, Frank B Hu, Jorge E Chavarro, Cuilin Zhang
Journal: BMJ (2016)

<b>Study question</b>&nbsp;What is the association between potato consumption before pregnancy and the risk of gestational diabetes mellitus (GDM)? <b>Methods</b>&nbsp;This prospective cohort study included 15 632 women from the Nurses' Health Study II (1991-2001). They had no previous GDM or chronic diseases before pregnancy. Consumption of potatoes and other foods was assessed every four years. Incident first time GDM was ascertained from self reports of a physician diagnosis of GDM, which was previously validated by medical records. <b>Study answer and limitations</b>&nbsp;Over the 10 year follow-up there were 854 incident cases of GDM among 21 693 singleton pregnancies. After adjustment for age, parity, and dietary and non-dietary factors, women who consumed more potatoes before pregnancy had higher rates of developing GDM. Substitution of two servings a week of total potatoes with other vegetables, legumes, and whole grain foods was significantly associated with a 9-12% lower risk of GDM. Consumption and diabetes were self reported, and severity of diabetes was unknown. More than 90% of women were white. A causal association cannot be assumed. <b>What this paper adds</b>&nbsp;Higher levels of potato consumption before pregnancy are associated with greater risk of GDM, and substitution of potatoes with other vegetables, legumes, or whole grain foods might lower the risk. <b>Funding, competing interests, data sharing</b>&nbsp;Funding was received from the Intramural Research Program of the <i>Eunice Kennedy Shriver</i> National Institute of Child Health and Human Development, the National Institutes of Health, and the American Diabetes Association (No 7-12-MN-34). The authors have no competing interests or additional data to share.
2015 ACC/AHA/HRS Advanced Training Statement on Clinical Cardiac Electrophysiology (A Revision of the ACC/AHA 2006 Update of the Clinical Competence Statement on Invasive Electrophysiology Studies, Catheter Ablation, and Cardioversion)
Authors: Douglas P. Zipes, Hugh Calkins, James P. Daubert, Kenneth A. Ellenbogen, Michael E. Field, John D. Fisher, Richard Ira Fogel, David S. Frankel, Anurag Gupta, Julia H. Indik, Fred M. Kusumoto, Bruce D. Lindsay, Joseph E. Marine, Laxmi S. Mehta, Lisa A. Mendes, John M. Miller, Thomas M. Munger, William H. Sauer, Win-Kuang Shen, William G. Stevenson, Wilber W. Su, Cynthia M. Tracy, Angela Tsiperfal
Journal: Journal of the American College of Cardiology (2015)
Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation
Authors: Marco Mielcarek, Terry Furlong, Paul V. O’Donnell, Barry E. Storer, Jeannine S. McCune, Rainer Storb, Paul A. Carpenter, Mary E. D. Flowers, Frederick R. Appelbaum, Paul J. Martin
Journal: Blood (2016)
Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer.
Authors: M L Rothenberg, R F Ozols, E Glatstein, S M Steinberg, E Reed, R C Young
Journal: Journal of Clinical Oncology (1992)

PURPOSE The primary goal of this trial was to evaluate the clinical activity of a high-dose cisplatin-based induction regimen for women with advanced-stage ovarian cancer. A secondary goal was to assess the use of whole-abdominal radiation as consolidative therapy in the subset of women left with less than 5 mm residual disease after completion of chemotherapy. PATIENTS AND METHODS Fifty consecutive patients with newly diagnosed, advanced-stage ovarian cancer received cisplatin 40 mg/m2/d and cyclophosphamide 200 mg/m2/d intravenously (IV) for 5 days, every 4 to 6 weeks. After three to four cycles of chemotherapy, patients who still had residual disease less than 5 mm in greatest diameter at second-look surgery were given whole-abdominal radiotherapy. RESULTS The overall response rate in 49 patients assessable for response was 61.3% (24.5% pathologic complete responses [pCRs], 32.7% pathologic partial responses [pPRs], and 4.1% clinical partial responses [cPRs]). Median survival for all patients was 23.4 months, and actuarial 4-year survival was 33.7% (95% confidence interval [CI], 21.8% to 48.1%). Multivariate analysis showed stage III and serous histology as independent favorable prognostic factors for survival. Median survival for stage III patients was 36.5 months, with an actuarial 4-year survival of 41.6% (95% CI, 25.5% to 59.6%). Median survival for stage IV patients was 12.0 months, with actuarial 4-year survival of 22.9% (95% CI, 9.5% to 45.5%). The major acute toxicities encountered were myelosuppression and peripheral neuropathy. Patients who received consolidative radiotherapy were at increased risk of developing late-onset enteropathy. CONCLUSIONS This regimen is active against advanced-stage ovarian cancer, but the associated toxicity is severe. Consolidative whole-abdominal radiation did not appear to prolong survival in the subset of women left with less than 5 mm residual disease after chemotherapy.
Allergic reactions in man.
Authors: C W Parker
Journal: Pharmacological Reviews (1982)

The general features of allergic drug reactions in man have recently been reviewed by Parker (85). By definition allergic drug reactions are produced by specific immunologic processes. Allergic drug reactions must be distinguished from adverse reactions due to overdosage, normal pharmacologic action, toxic metabolite formation, idiosyncrasy, nonspecific release of pharmacologic effector molecules, or drug interactions. The clinical manifestations of drug allergy are quite protean. In addition to classical manifestations of allergy such as serum sickness, anaphylaxis, contact dermatitis or urticaria, drug allergy may produce hemolytic anemia, thrombocytopenia, granulocytopenia, hepatitis, nephritis, pneumonitis, vasculitis, or neuritis where a single organ or cell type is affected. While many drugs produce reactions with suggestive of allergy, definitive experimental evidence either for or against mechanism is usually not available. Some of these reactions may involve allergic mediators released or produced nonimmunologically through pharmacologic, osmotic, or toxic effects on cells involved in immune inflammation (mast cells, basophils, phagocytes, and lymphocytes) or through nonspecific activation of effector molecules in extracellular fluid such as the complement proteins. Drugs may also induce the formation of autoantibodies through mechanisms that are largely obscure, but may in some instances involve the direct participation of the drug as a hapten and in other instances occur indirectly through a pharmacologic or toxic action on the cells responsible for immune homeostasis.
急性非代償性心不全における心腎救済試験: 心不全臨床研究ネットワークCARRESS-HF結果
Authors: A Bart Bradley, R Goldsmith Steven, L Lee Kerry, W Stevenson Lynne, M O’Connor Christopher, A Bull David, M Redfield Margaret, Deswal Anita, L Rouleau Jean, M Lewinter Martin, O Ofili Elizabeth, M Givertz Micheal, J Semigran Marc, H Chen Horng, F Hernandez Adrian, J Anstrom Kevin, E Mcnulty Steven, J Velazquez Eric, M Mascette Alice, Braunwald Eugene
Journal: Circulation (2012)
High-Time Chemotherapy or High Time for Low Dose
Authors: Barton A. Kamen, Eric Rubin, Joseph Aisner, Eli Glatstein
Journal: Journal of Clinical Oncology (2000)

Article Tools EDITORIAL Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2000.18.16.2935 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 10944125 High-Time Chemotherapy or High Time for Low Dose Barton A. Kamen, MD, PhDxBarton A. KamenSearch for articles by this author , Eric Rubin, MDxEric RubinSearch for articles by this author , Joseph Aisner, MDxJoseph AisnerSearch for articles by this author Eli Glatstein, MDxEli GlatsteinSearch for articles by this author Show More Cancer Institute of New Jersey Robert Wood Johnson Medical School New Brunswick, NJUniversity of Pennsylvania School Medical Center Philadelphia, PA https://doi.org/10.1200/JCO.2000.18.16.2935 First Page Full Text PDF Figures and Tables © 2000 by American Society of Clinical Oncology
Impact of treatment characteristics on response of different breast cancer subtypes: Pooled multilayer analysis of the German neoadjuvant chemotherapy trials.
Authors: G. Von Minckwitz, M. Untch, E. Nueesch, M. Kaufmann, S. Kuemmel, P. A. Fasching, W. Eiermann, J. U. Blohmer, S. Loibl, P. Jueni
Journal: Journal of Clinical Oncology (2010)

501 Background: Eight German neoadjuvant chemotherapy trials including 6,625 patients with uniform protocol and outcome definitions were conducted between 1998 and 2006 with pathological complete response (pCR) as primary endpoint. Methods: We used a more sophisticated multilevel model with random effects at the level of trials and regimens to pooled individual patient data. The model fully accounted for heterogeneity between trials in pCR. The analysis was restricted to a data set of 3,332 patients from 7 trials and 12 treatment arms with complete baseline parameters and no confounding by treatment indication based on interim response. Results: pCR was associated with an increase in cycle numbers (odds ratio [OR ] 1.2 with every two additional cycles; p = 0.009), with regimens using higher cumulative anthracycline doses (≥ 300 mg/m2 doxorubicin or ≥ 450 mg/m2 epirubicin; OR 1.6; p = 0.002), regimens with higher cumulative taxane doses (≥ 400 mg/m2 docetaxel or ≥ 700 mg/m2 paclitaxel; OR 1.6; p = 0.009), and with capecitabine containing regimens (OR 1.62; p = 0.022). Concurrent trastuzumab in patients with HER2-positive tumors increased the odds of pCR 3.2fold (p < 0.001). The association of pCR with increase in cycle numbers was more pronounced in hormone receptor (HR)-positive tumors (OR 1.35) than in HR-negative tumors (OR 1.04; p for interaction = 0.046). The anthracycline dose effect was pronounced in HER2-negative tumors (OR 1.61), as compared with HER2-positive tumors (OR 0.83; p for interaction p = 0.14). There was no evidence that the effect of taxane dose (p for interaction ≥ 0.64) and the effect of capecitabine (p for interaction ≥ 0.57) varied between subtypes. PCR was not different after 4, 8 or 12 trastuzumab cycles (OR per 4 cycles increase 0.97, p = 0.87) overall or in subgroups. Conclusions: We postulate that HR-positive tumors benefit more from longer neoadjuvant treatments, HER2-negative tumors more from higher anthracycline doses, triple negative tumors from short-term higher dose taxane and anthracycline based treatment, HER2-positive tumors already from a limited number of 4 trastuzumab cycles, and all subtypes from the addition of capecitabine. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca, Novartis, Roche, sanofi-aventis Amgen, AstraZeneca, Novartis, Roche, sanofi-aventis AstraZeneca, Roche
Junior doctors’ dispute is result of financial mismanagement, Labour says
Authors: Gareth Iacobucci
Journal: BMJ (2015)

Ministerial threats to impose a new contract on junior doctors in England risk taking the NHS back to “the bad old days” and are punishing doctors for the government’s own financial mismanagement of the service, Labour’s new shadow health secretary has said.

In a speech at the Labour Party’s conference in Brighton this week, Heidi Alexander also warned Prime Minister David Cameron to be prepared for “the fight of your life” over plans to further squeeze NHS funding.

In her first major speech since being appointed to the shadow health role by …
Comparative Study of Intestinal Adenocarcinomas of Animals and Man&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Carolyn H. Lingeman, M.D., F. M. Garner
Journal: JNCI Journal of the National Cancer Institute (1972)

Spontaneous adenocarcinomas are infrequent in intestines of animals compared to man. They occur more often in dogs than in other animals. These canine carcinomas are similar to those of man in that most originate in the distal colon and rectum, sometimes in polypoid adenomas. They are moderately well differentiated or anaplastic, sometimes mucin-producing adenocarcinomas that metastasize to lymph nodes, liver, and other structures. More males than females develop carcinomas in the rectum, but there are no sex differences for other locations. They are more frequent in older dogs and there is no known breed preference. In contrast to man and dogs, the largest proportion of primary adenocarcinomas of the intestines of cats originates in the ileum or jejunum (75%). They frequently metastasize to lymph nodes, liver, or other locations. Most occur in older cats of both sexes and there is no known breed preference. Epidemic adenocarcinomas of the small intestine of sheep in New Zealand and Australia appear to offer unusual opportunities for investigations of etiologic mechanisms that might be important in intestinal carcinogenesis in man. Spontaneous adenocarcinomas of intestines are rare in most species of laboratory rodents, except for occasional “outbreaks” in colonies of rats or hamsters. Most laboratory rodents are susceptible to induction of adenomas and adenocarcinomas of the small and large intestines by a variety of natural and synthetic chemical substances. Histologic features of carcinogen-induced intestinal adenocarcinomas of rats and other rodents are similar to those of spontaneous adenocarcinomas of dogs, cats, and man.
Strong Maternal Effects on Gene Expression in<i>Arabidopsis lyrata</i>Hybrids
Authors: Elin Videvall, Nina Sletvold, Jenny Hagenblad, Jon Ågren, Bengt Hansson
Journal: Molecular Biology and Evolution (2015)

Hybridization between populations or species can have pronounced fitness consequences. Yet little is known about how hybridization affects gene regulation. Three main models have been put forward to explain gene expression patterns in hybrids: additive, dominance, or parental effects. Here, we use high throughput RNA-sequencing to examine the extent to which hybrid gene expression follows predictions by each of the three models. We performed a reciprocal crossing experiment between two differentiated populations of the perennial herb Arabidopsis lyrata and sequenced RNA in rosette leaves of 12-week-old plants grown in greenhouse conditions. The two parental populations had highly differentiated gene expression patterns. In hybrids, a majority of genes showed intermediate expression relative to that of their parental populations (i.e., additive effects), but expression was frequently more similar to the maternal than to their paternal population (i.e., maternal effects). Allele-specific expression analyses showed that in the vast majority of cases, genes with pronounced maternal effect expressed both the maternal and the paternal allele. Maternal effects on hybrid gene expression have rarely been documented previously and our study suggests it could be more common than previously assumed. Whether the maternal effect on gene expression persists to later life-stages, and whether the variation in gene expression is manifested in other aspects of the phenotype, remain to be elucidated. Our findings are relevant for understanding the consequences of outbreeding and hybridization and open up several questions for future studies.
OC-030 Effective Stratification Of Hepatocellular Carcinoma Risk In Primary Biliary Cirrhosis: Results Of A Multi-centre International Study
Authors: PJ Trivedi, W Lammers, H van Buuren, H Janssen, P Invernizzi, PM Battezzati, A Floreani, A Pares, C Ponsioen, C Corpechot, R Poupon, M Mayo, J Talwalkar, A Burroughs, F Nevens, A Mason, T Bruns, K-K Li, K Kowdley, T Kumagi, A Cheung, A Lleo, N Cazagon, I Franceschet, L Caballería, K Boonstra, E de Vries, M Imam, G Pieri, P Kanwar, K Lindor, B Hansen, G Hirschfield
Journal: Gut (2014)

<h3>Introduction</h3> Hepatocellular carcinoma (HCC) is an important but infrequent outcome in primary biliary cirrhosis (PBC). Improved risk evaluation is an important goal for stratified surveillance. <h3>Methods</h3> Risk-factor analysis of the ‘Global PBC Study Group’ comprising 15 centres across North America and Europe spanning &gt;40-years follow-up was performed using Cox proportional hazards model, logistic regression and Kaplan-Meier estimates (SPSSv21). <h3>Results</h3> Of 3546 patients with PBC (med. follow-up 8.6 yrs; IQR 4.4–14.1), 131 developed HCC. Excluding those who developed HCC within 12 months of PBC diagnosis (n = 23), median time to HCC was 12.7 yrs (6.9–16.8) and subsequent survival 1.1 yrs. (0.2–2.7). At diagnosis, factors associated with HCC development were male gender (adj. HR: 4.4;1.4–12.2, p = 0.014) and thrombocytopenia (adj. HR: 4.5;1.4–14.8, p = 0.012). Use of ursodeoxycholic acid per-se was not associated with future risk of HCC, but stratification of risk by biochemical response at 12 months was effective by Rotterdam (adj. HR: 8.9;2.1–37.3, P = 0.003), Paris-I (adj. HR: 7.6;2.0–29.0, p = 0.003) or Toronto criteria (HR: 5.6;1.6–18.8, P = 0.006). Five (4.6 vs. 0.2%) and 10-year (13%vs.1.9%) HCC incidence was significantly increased for biochemical non-responders (p = 2.2 × 10<sup>–9</sup>), and by multivariate analysis non-response remained the only significant risk factor. <h3>Conclusion</h3> Our uniquely powered cohort allows robust demonstration that 12-month biochemical non-response is associated with an increased risk of developing HCC in PBC. Routine surveillance in those achieving biochemical response is unlikely cost-effective. <h3>Disclosure of Interest</h3> None Declared.